Global Neurostimulation Devices Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Spinal Cord Stimulation Device, Deep Nerve Stimulation Device, Vagus Nerve Stimulation Device, Sacral Nerve Stimulation Device), By Application (Pain Management, Sleep Apnea, Cochlear Implants, Neurology), By End-Users (Hospitals & Clinics, Ambulatory Care Centers), And By Geography - Forecasts From 2021 To 2026

Published:  Jul 2021 Report Code: KSI061611642 Pages: 115

The global neurostimulation devices market is expected to grow at a compound annual growth rate of 10.08% over the forecast period to reach a market size of US$12.796 billion in 2026 from US$6.623 billion in 2019.

Neurostimulation devices are implantable programmable medical devices that deliver electrical stimulation to specific parts of the patient's brain, spinal cord, or peripheral nervous system for the treatment of various conditions such as chronic pain, movement disorders, epilepsy, and Parkinson's disease. Neurostimulation is used as a key element in neural prosthetics for hearing aids, artificial vision, artificial limbs, brain-machine interfaces, etc. the growth in the neurostimulation devices market may be attributed to the increasing prevalence of chronic neuromuscular disorder and the rising adoption of these devices by the physicians. Recent advances in neurotechnologies and neuroimaging have resulted in a rapid rise in the use of neurostimulation devices for the treatment of an increasingly wide range of neurologic and psychiatric disorders thus, leading to the robust growth of the market for the given forecast period. However, stringent regulations of the neurostimulation devices and lack of skilled professionals for performing the surgeries might restrain the market growth during the given time frame. With the increasing investments in the development of novel and advanced neurostimulation devices, the market is expected to surge at an exponential rate, during the forecast period.

GLOBAL NEUROSTIMULATION DEVICES MARKET, US$ billion, 2019 to 2026

Source: Knowledge Sourcing Intelligence Analysis

Hearing Loss and deafness.

The market is expected to surge in the coming years, due to the rise in the number of people, suffering from hearing loss and other related concerns. According to the data given by the World Health Organisation, approx. 2.5 billion people are expected to have some sort of hearing loss and an estimated number of 700 million would require hearing rehabilitation, by the year 2050. There has been an urge in the need for advanced and safer hearing loss devices and solutions. More than 1 billion young adult population are at high risk of avoidable, permanent hearing loss due to unsafe listening practices and lack of availability of high-quality devices and solutions. Major companies and organizations have been providing high-quality neurostimulation devices for their customers. Cochlear implants are expected to generate significant demand, in the coming years. For instance, Cochlear, one of the major players in the market, has been providing implantable hearing solutions, for decades. These developments are expected to have a positive impact on the market, in the coming years. In June 2021, Oticon Medical, one of the key players in the market, announced that the United States Food and Drug Administration had granted and provided premarket approval to the firm's Neuro System to treat and cure individuals 18 years or above. The firm had been intended to treat the patients with bilateral severe-to-profound sensorineural hearing loss. This system is known Neuro Cochlear Implant System.

GLOBAL NEUROSTIMULATION DEVICES Market SHARE, BY APPLICATION

(sample figure)

                                                2019                                                                                            2026

Latest Developments.

Major companies, research institutions, and organizations have been investing a significant sum of capital into the development of novel, advanced, and innovative neurostimulation devices for their patients and customers. 

  • In February 2021, Mainstay Medical Holdings PLC announced that it had closed an equity financing which had raised proceeds of around US$108 million. The company had stated that they intend to use the funds to support and enhance the commercial launch of the company's major ReActive8 in the United States, general operations, increasing expansion in Australia and Europe, and additional post-market research and clinical studies. ReActiv8 had been an implantable restorative neurostimulation system, for patients suffering from chronic low back pain. This development is expected to have a positive impact on the market, in the coming years.
  • In June 2021, electroCore Inc., a commercial-stage bioelectronic medicine company, announced that it had entered into a massive agreement with Kromax International Corporation, intending to serve as the exclusive distributor of the gammaCore Sapphire. The device had been a non-invasive vagus nerve stimulator, and the distribution agreement is specific to China and Taiwan. The company's major aim is to enhance the lives and health of its patients. This development is expected to enhance the company's market share, in the Asia Pacific region.

Increasing Geriatric Population

The market is expected to surge in the coming years, due to the increasing geriatric population, globally. According to the data given by the United Nations, there were an estimated 703 million people, that were aged 65 years or over in 2019. The UN report also stated that the number of older people, globally, is expected to double to an estimated 1.5 million in the year 2050. An aging population is expected to put significant financial pressure on old-age support systems. Older people tend to suffer from chronic pain, spinal cord pain, nerve pain, and hearing loss. With the rise in the development of novel and advanced neurostimulator devices and systems, the demand for its use for older people is expected to surge. According to several official studies conducted, there had been an improvement in the hearing capabilities, with the use of cochlear implants in older people. This development is expected to enhance the market growth in the coming years.

Global Neurostimulation Devices Market Scope:
Report Metric Details
 Market size value in 2019  US$6.623 billion
 Market size value in 2026  US$12.796 billion
 Growth Rate  CAGR of 10.08% from 2019 to 2026
 Base year  2019
 Forecast period  2021–2026
 Forecast Unit (Value)  USD Billion
 Segments covered  Type, Application, End-User, And Geography
 Regions covered  North America, South America, Europe, Middle East and Africa, Asia Pacific
 Companies covered  INNOPSYS, Abbott, Synergia Medical, Medtronic, Stimwave LLC, Boston Scientific,   LivaNova, NeuroSigma, Axonics, Neuronetics
 Customization scope  Free report customization with purchase

 

 Segmentation:

  • By Type
    • Spinal Cord Stimulation Device
    • Deep Nerve Stimulation Device
    • Vagus Nerve Stimulation Device
    • Sacral Nerve Stimulation Device
  • By Application
    • Pain Management
    • Sleep Apnea
    • Cochlear Implants
    • Neurology
  • By End-User
    • Hospitals & Clinics
    • Ambulatory Care Centers
  • By Geography
    • North America
      • USA
      • Canadá
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • UK
      • Germany
      • France
      • Italy
      • Others
    • Middle East and Africa
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Thailand
      • Taiwan
      • Indonesia
      • Others

Frequently Asked Questions (FAQs)

Q1. What are the growth prospects for the neurostimulation devices market?
A1. The neurostimulation devices market is expected to grow at a CAGR of 10.08% over the forecast period.


Q2. What will be neurostimulation devices market size by 2026?
A2. The global neurostimulation devices market is expected to reach a total market size of US$12.796 billion by 2026.


Q3. What is the size of the global neurostimulation devices market?
A3. Neurostimulation Devices Market was valued at US$6.623 billion in 2019. 


Q4. How is the neurostimulation devices market segmented?
A4. The global neurostimulation devices market has been segmented by type, application, end-user, and geography.


Q5. What factors are anticipated to drive the neurostimulation devices market growth?
A5. The growth in the neurostimulation devices market may be attributed to the increasing prevalence of chronic neuromuscular disorders and the rising adoption of these devices by physicians.

1. Introduction
1.1. Market Definition
1.2. Market Segmentation

2. Research Methodology
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. Global Neurostimulation Devices Market Analysis, By Type 
5.1. Introduction
5.2. Spinal Cord Stimulation Device
5.3. Deep Nerve Stimulation Device
5.4. Vagus Nerve Stimulation Device
5.5. Sacral Nerve Stimulation Device

6. Global Neurostimulation Devices Market Analysis, By Application
6.1. Introduction
6.2. Pain Management
6.3. Sleep Apnea
6.4. Cochlear Implants
6.5. Neurology

7. Global Neurostimulation Devices Market Analysis, By End-User
7.1. Introduction
7.2. Hospitals & Clinics
7.3. Ambulatory Care Centers

8. Global Neurostimulation Devices Market Analysis, By Geography 
8.1.  Introduction
8.2.  North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. UK
8.4.2. France
8.4.3. Germany
8.4.4. Italy
8.4.5. Others
8.5. The Middle East and Africa 
8.6. Asia Pacific
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. Thailand
8.6.5. Taiwan
8.6.6. Indonesia
8.6.7. Others

9.  Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2.  Emerging Players and Market Lucrativeness
9.3.  Mergers, Acquisitions, Agreements, and Collaborations
9.4.  Vendor Competitiveness Matrix

10. Company Profiles
10.1. INNOPSYS
10.2. Abbott
10.3. Synergia Medical
10.4. Medtronic
10.5. Stimwave LLC
10.6. Boston Scientific
10.7. LivaNova
10.8. NeuroSigma
10.9. Axonics
10.10. Neuronetics

INNOPSYS

Abbott

Synergia Medical

Medtronic

Stimwave LLC

Boston Scientific

LivaNova

NeuroSigma

Axonics

Neuronetics

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us